GWSG
NTLA icon

GPS Wealth Strategies Group’s Intellia Therapeutics NTLA Stock Holding History

GPS Wealth Strategies Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$899 Buy
+100
New +$1.38K ﹤0.01% 555

Other funds holding NTLA

ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

GPS Wealth Strategies Group's NTLA Position: Q4 2025 in Review

GPS Wealth Strategies Group opened a new position in Intellia Therapeutics (NTLA) in Q4 2025: 100 shares worth $899. The stake represents ﹤0.01% of the portfolio and ranks #555 among its holdings.

293 funds tracked by Wall St. Rank hold NTLA as of Q4 2025.

  • GPS Wealth Strategies Group held 100 shares of Intellia Therapeutics worth $899 as of Q4 2025.
  • Intellia Therapeutics was a new GPS Wealth Strategies Group position in Q4 2025.
  • Intellia Therapeutics made up ﹤0.01% of GPS Wealth Strategies Group's portfolio in Q4 2025, its #555 holding.
  • 293 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2025.

Based on GPS Wealth Strategies Group's 13F filing for Q4 2025, filed 6 Feb 2026.